The AntiHelix consortium includes five renowned academic laboratories with a long-standing interest in the field of DNA helicases (CNR, UCPH, USFD, ELETTRA, SLU), with a wide range of technical and scientific expertises, ranging from cell biology to biochemistry to structural biology, and working on different but interconnected DNA helicases; one world leader in the field of single molecules biophysical studies of protein-DNA interaction (VU); one research group dedicated to clinical oncology studies (UKESSEN); three companies involved in various stages of drug discovery (LDC, EDELRIS, PPSC) and one company developing state-of-the-art instrumentation for biophysical studies (LUMICKS). This web of research groups and institutions will provide a thriving and innovative scientific environment that potentially offers unique opportunities to develop a strong research programme at the interface between different disciplines (cell biology, biochemistry, structural biology, biophysics, single molecule approaches, optics, medicinal chemistry, drug design, computational biology/chemistry, clinical oncology) with complementary experimental approaches and a strong emphasis on translation of scientific results.

Beneficiaries

Partners

Project Officers: Mattia Zilli and Giuliana Donini


Coordinator: Francesca Pisani

Deputy Coordinator: Ian Hickson

Training Coordinator: Ying Liu

Website Manager and Outreach Coordinator: Silvia Onesti


Supervisory Board

Voting members:

CNRFrancesca M. Pisani
ELETTRASilvia Onesti
UCPHYing Liu
VUGijs Wuite
USFDCyril Sanders
UKESSENIris Helfrich
LCDBert Klebl
EDELRISDidier Roche
LUMICKSMattijs de Groot
ESR Rep1Francesca Scommegna
ESR Rep2Mark Wever

Non-voting members:

WUSTLAlessandro Vindigni
SISSA MLSimona Cerrato
UVANAndrea Riccio
UGAJean Francois Poisson
UniTSEnzo Alessio
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 859853